-
Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip
•
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year (YOY) increase in global sales to DKK83.3 billion (USD11.42 billion) in constant exchange rate terms. The company saw strong sales growth in International Operations, up 10% YOY, and in North America, up 24% YOY. Diabetes…
-
Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved
•
Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab),…
-
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
•
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48% year-on-year (YOY) increase in total global revenues to USD22.16 billion in constant currency terms. The company saw strong growth across various disease areas and key products. Business Performance Key Products COVID-19 Portfolio Geographical Performance Challenges…
-
Astellas Pharma Posts 17% Q1 Sales Growth Driven by Xtandi and Padcev
•
Japan-based Astellas Pharma Inc. (TYO: 4503) reported a 17.1% year-on-year (YOY) increase in global sales revenues to JPY 381.79 billion (USD 2.89 billion) for the fiscal Q1 period ending June 30, 2022. The growth was driven by strong performance from key oncology and nephrology products. Core Product Highlights Regional GrowthGreater…
-
HutchMed’s H1 2022 Oncology Sales Surge 82% on Strong Product Performance
•
China-based biopharma HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) reported strong financial results for the first half of 2022, with oncology product sales soaring 82% year-on-year (YOY) to USD 87.4 million. The company expanded its commercial team to 800 staff, driving growth across its key products. Product Sales Breakdown Revenue…
-
Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion
•
France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3 billion), marking an 8.1% year-on-year (YOY) increase in constant exchange rate (CER) terms. Growth was driven by the anti-allergy drug Dupixent (dupilumab) and strong performances in rare diseases, vaccines, and consumer healthcare. Pharmaceuticals and Vaccines…
-
Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth
•
US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD 14.6 billion, marking a 31% increase in constant exchange rate (CER) terms. The growth was driven by recovery from COVID-19 disruptions and contributions from the COVID-19 antiviral drug Lagevrio (molnupiravir). Key Growth Drivers China PerformanceChina…
-
Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in overall group sales at constant exchange rates (CER) to CHF 32.3 billion (USD 33.3 billion) for the first half of 2022. The growth was driven by new drugs for hemophilia, cancer, and neurological disorders, which…
-
J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year (YOY) sales growth in constant currency to $24.02 billion but a 23.3% net profit drop to $4.81 billion. CFO Joseph Wolk cited the strong dollar and China’s COVID-19 lockdowns as key factors, prompting a full-year…
-
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
•
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant currency terms to $12.79 billion in Q2 2022, though dollar sales dipped 1% due to currency strength. Earnings per share (EPS) rose 1%, or 10% excluding the $20.7 billion Roche stake sale in November 2021.…
-
Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss
•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the year ended March 31, 2022), with revenues reaching RMB 20.57 billion (USD 3 billion), up 32.6% year-on-year (YOY). The growth was driven by the pharmaceutical self-operation business and medical and digital service business. However, the…
